Clinical experience with dual pathway inhibition therapy: case series and mini review

BACKGROUND: Dual pathway inhibition (DPI) with rivaroxaban 2.5 mg twice daily plus aspirin has demonstrated reductions in major adverse cardiovascular and limb events in eligible patients with chronic coronary artery disease (CAD), peripheral artery disease, or both. Patients with polyvascular disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Geisler, Tobias, Branch, Kelley, Nikol, Sigrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278337/
https://www.ncbi.nlm.nih.gov/pubmed/35854882
http://dx.doi.org/10.1093/ehjcr/ytac201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278337/
https://www.ncbi.nlm.nih.gov/pubmed/35854882
http://dx.doi.org/10.1093/ehjcr/ytac201

Ejemplares similares